AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,000.00
+280.00 (4.17%)
Apr 10, 2026, 3:30 PM KST

AptaBio Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22
196,654251,341171,234201,805237,483
Market Cap Growth
-1.94%46.78%-15.15%-15.02%-
Enterprise Value
183,886240,559146,945152,862-
Last Close Price
7000.009350.006370.009050.0010650.00
Forward PE
-78.1078.1078.1078.10
PS Ratio
53.1867.9750.95623.114911.46
PB Ratio
4.175.333.163.294.54
P/TBV Ratio
4.265.453.163.324.54
EV/Sales Ratio
49.7365.0543.72471.99-
Debt / Equity Ratio
0.090.090.140.230.01
Net Debt / Equity Ratio
-0.27-0.27-0.44-0.63-0.32
Net Debt / EBITDA Ratio
0.850.851.192.381.85
Net Debt / FCF Ratio
0.830.831.942.522.11
Asset Turnover
0.050.050.040.00-
Inventory Turnover
5.755.75---
Quick Ratio
1.841.841.6765.1016.58
Current Ratio
2.612.611.7970.2719.63
Return on Equity (ROE)
-32.25%-32.25%-50.84%-21.21%-
Return on Assets (ROA)
-14.13%-14.13%-15.24%-14.22%-
Return on Capital Employed (ROCE)
-30.90%-30.90%-35.80%-18.40%-17.30%
Earnings Yield
-8.31%-6.50%-17.16%-5.98%-4.45%
FCF Yield
-7.80%-6.10%-7.24%-7.65%-3.32%
Buyback Yield / Dilution
-14.40%-14.40%-5.57%-0.05%-
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.